These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16798693

  • 41. [Characterization of macrolide-resistance mediated by transposable elements Tn1545 and Tn917 in clinical Isolates of Streptococcus pneumoniae].
    Wu WJ, Hong XH, Zhang H, Jiang YQ, Lu Q, Ni YX.
    Zhonghua Yi Xue Za Zhi; 2006 Mar 07; 86(9):605-8. PubMed ID: 16681905
    [Abstract] [Full Text] [Related]

  • 42. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.
    de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A.
    Antimicrob Agents Chemother; 2001 Dec 07; 45(12):3504-8. PubMed ID: 11709331
    [Abstract] [Full Text] [Related]

  • 43. Distribution of macrolide resistance mechanisms in Bulgarian clinical isolates of Streptococcus pyogenes during the years of 2013-2016.
    Muhtarova AA, Gergova RT, Mitov IG.
    J Glob Antimicrob Resist; 2017 Sep 07; 10():238-242. PubMed ID: 28735056
    [Abstract] [Full Text] [Related]

  • 44. [The correlation between phenotypes and genotypes of macrolides, lincosamides and streptogramins B resistance in Staphylococcus aureus].
    Młynarczyk G, Młynarczyk A, Szymanek K, Bilewska A, Luczak M.
    Med Dosw Mikrobiol; 2007 Sep 07; 59(1):17-25. PubMed ID: 17601027
    [Abstract] [Full Text] [Related]

  • 45. Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil.
    d'Oliveira RE, Barros RR, Mendonça CR, Teixeira LM, Castro AC.
    Microb Drug Resist; 2003 Sep 07; 9(1):87-91. PubMed ID: 12705687
    [Abstract] [Full Text] [Related]

  • 46. Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey.
    Aktas Z, Aridogan A, Kayacan CB, Aydin D.
    J Microbiol; 2007 Aug 07; 45(4):286-90. PubMed ID: 17846580
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes.
    Drago L, Ripa S, Zampaloni C, De Vecchi E, Vitali LA, Petrelli D, Prenna M.
    Chemotherapy; 2005 Aug 07; 51(5):268-71. PubMed ID: 16088124
    [Abstract] [Full Text] [Related]

  • 49. [Resistance to macrolides in the species Streptococcus pyogenes in the Czech Republic in 1996-2003].
    Urbásková P, Jakubů V, Pracovní skupina pro monitorování antibiotické rezistence.
    Epidemiol Mikrobiol Imunol; 2004 Nov 07; 53(4):196-202. PubMed ID: 15633541
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Presence of plasmid pA15 correlates with prevalence of constitutive MLS(B) resistance in group A streptococcal isolates at a university hospital in southern Taiwan.
    Liu YF, Wang CH, Janapatla RP, Fu HM, Wu HM, Wu JJ.
    J Antimicrob Chemother; 2007 Jun 07; 59(6):1167-70. PubMed ID: 17460027
    [Abstract] [Full Text] [Related]

  • 52. Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.
    Crotti D, Rossetti R, Braga PC.
    Drugs Exp Clin Res; 2004 Jun 07; 30(1):17-26. PubMed ID: 15134387
    [Abstract] [Full Text] [Related]

  • 53. Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan: report of a countrywide surveillance study.
    Hotomi M, Billal DS, Shimada J, Yamauchi K, Fujihara K, Yamanaka N, Surveillance Subcommittee of the Japan Society for Infectious Diseases in Otolaryngology.
    J Infect Chemother; 2005 Feb 07; 11(1):48-51. PubMed ID: 15729489
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].
    Gür D, Mülazimoğlu L, Unal S, e-BASKETT-II Calişma Grubu.
    Mikrobiyol Bul; 2007 Jan 07; 41(1):1-9. PubMed ID: 17427547
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Decrease of erythromycin resistance in group A streptococci by change of emm distribution.
    Koh EH, Kim S, Lee NY.
    Jpn J Infect Dis; 2008 Jul 07; 61(4):261-3. PubMed ID: 18653965
    [Abstract] [Full Text] [Related]

  • 60. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004.
    Tamayo J, Pérez-Trallero E, Gómez-Garcés JL, Alós JI, Spanish Group for the Study of Infection in the Primary Health Care Setting.
    J Antimicrob Chemother; 2005 Oct 07; 56(4):780-2. PubMed ID: 16120627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.